Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Diane McNeil

Nurse Practitioner, Family Goose Creek, SC Nurse Practitioner

NPI 1801334412 CMS profile 11001171

119 Springhall Dr, Goose Creek, SC 29445

Open in the dashboard

General payments

$10,449

451 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Diane McNeil of Goose Creek, SC is reported in the CMS Open Payments database as having received $10,449 across 451 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,626 76
2024 General $2,341 101
2023 General $2,732 113
2022 General $2,560 96
2021 General $1,190 65

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Diane McNeil
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Diane McNeil were reported at $1,626. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Diane McNeil Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,190 $124 $35–$379 $132
2022 $2,560 $141 $44–$430 $149
2023 $2,732 $154 $49–$476 $160
2024 $2,341 $165 $51–$504 $164
2025 $1,626 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,902 119 payments
  2. AstraZeneca Pharmaceuticals LP $1,423 37 payments
  3. Lilly USA, LLC $942 47 payments
  4. Novo Nordisk Inc $881 43 payments
  5. GlaxoSmithKline, LLC. $798 25 payments
  6. Pfizer Inc. $540 26 payments
  7. Biohaven Pharmaceutical Holding Company Ltd. $441 12 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $334 17 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $299 15 payments
  10. Salix Pharmaceuticals, a division of Bausch Health US, LLC $245 15 payments
  11. Other $2,644 95 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,449 451 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR $1,079 66 payments
  2. FARXIGA $916 17 payments
  3. BREZTRI $749 15 payments
  4. MOUNJARO $715 34 payments
  5. UBRELVY $581 32 payments
  6. NURTEC ODT $501 15 payments
  7. RYBELSUS $483 29 payments
  8. Ozempic $461 28 payments
  9. QULIPTA $454 28 payments
  10. TRELEGY ELLIPTA $409 20 payments
  11. Other $7,420 306 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 59 drugs

Part D claims

2,178

Median for Nurse Practitioner: 389

Drug cost

$203,015

Median for Nurse Practitioner: $21,885

Branded share of claims

18.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 51 $69,905
Farxiga Dapagliflozin Propanediol Brand 19 $32,135
Trulicity Dulaglutide Brand 28 $28,609
Jardiance Empagliflozin Brand 28 $23,368
Ozempic Semaglutide Brand 22 $20,493
Humulin 70-30 Insulin Nph Hum/Reg Insulin Hm Brand 12 $2,610
Levothyroxine Sodium Generic 113 $2,194
Atorvastatin Calcium Generic 189 $1,783
Albuterol Sulfate Hfa Albuterol Sulfate Brand 70 $1,741
Omeprazole Generic 77 $1,322

The 10 drugs with the highest cost, of 59 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$44,558

Of which drugs: $3,066

Medicare patients

195

Average age 72

Services billed

1,153

127 women, 68 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 45%
Arthritis 34%
Chronic kidney disease 17%
Ischemic heart disease 15%
COPD 15%
Depression 13%
Heart failure 11%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Influenza vaccine, trivalent derived from cell cultures 90661 Office 29 29 $1,047

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 30 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $315
$315 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $243
$243 19 —
AREXVY
  • GlaxoSmithKline, LLC. $135
$135 — —
EPKINLY
  • Genmab U.S., Inc. $111
$111 — —
MOUNJARO
  • Lilly USA, LLC $102
$102 51 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 30 with Patron

Records

451 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record